In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.

Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.

Magazine

Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.

At 6 h xyloglucan produced a statistically significant higher decrease in the mean number of type 6 and 7 stools compared with diosmectite and S. boulardii.

Read more
CPHI 2025

Noventure will attend the CPHI (Frankfurt, 28-30 October 2025) 

Arrange a meeting with us to learn more about our products and license availability in the different countries.

¡Meet us at our Stand #4.1L30!


Contact us: https://noventure.com/contact-us

Read more

Let's meet in ...

2025, Oct 28

CPHI 2025